Abivax (ABVX) Operating Expenses (2024 - 2026)

Abivax's Operating Expenses history runs 3 years deep, the most recent figure standing at -$67.4 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 32.96% year-over-year to -$67.4 million; the TTM figure through Mar 2026 stood at $281.5 million (up 44.68% YoY), while the FY2025 annual figure was $291.7 million, up 47.23% from the prior year.
• Operating Expenses was -$67.4 million for Q1 2026 at Abivax, down from $499.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $499.6 million in Q4 2025 to a low of -$96.7 million in Q3 2025.
• Historically, Operating Expenses has averaged $47.4 million across 3 years, with a median of -$50.7 million in 2025.
• Biggest YoY gain for Operating Expenses was 44.4% in 2025; the steepest drop was 71.01% in 2025.
• A 3-year view of Operating Expenses shows it stood at $346.0 million in 2024, then surged by 44.4% to $499.6 million in 2025, then plunged by 113.49% to -$67.4 million in 2026.
• The last three Operating Expenses figures came in at -$67.4 million (Q1 2026), $499.6 million (Q4 2025), and -$96.7 million (Q3 2025), per Business Quant data.